Enliven Therapeutics, Inc. 4

Helen Louise Collins, CMO of Enliven Therapeutics (ELVN), exercised 5,000 stock options at $2.48 and sold 5,000 shares of common stock at around $43–45 on June 17, 2026, leaving her with 30,000 shares owned.

On June 17, 2026, Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., exercised 5,000 stock options at an exercise price of $2.48 per share, acquiring 5,000 shares of common stock, and on the same day sold an aggregate 5,000 shares of common stock in three open-market transactions at weighted average prices of $42.827, $43.8701, and $44.743 per share under a pre-arranged Rule 10b5-1 trading plan. The gross value of the option exercise was approximately $12,400, while the total sale proceeds were roughly $219,200. Following these transactions, she directly owned 30,000 shares of Enliven common stock, including certain restricted stock units that each represent a contingent right to receive one share of common stock, with an estimated post-transaction holding value of about $1.28 million based on the prevailing sale prices. The options exercised were fully vested and exercisable at the time of the transaction, and the sales were executed in multiple trades within the stated price ranges.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

sec

Accession

0001701247-26-000010

Alert Tier

6